| 我国生物医药科技成果转化的制约因素分析和战略规划建议 |
| |
| 引用本文： | 孙立,孟海华.我国生物医药科技成果转化的制约因素分析和战略规划建议[J].科技管理研究,2023(2):144-150. |
| |
| 作者姓名： | 孙立 孟海华 |
| |
| 作者单位： | 上海市投资促进服务中心（上海市中小企业上市促进中心）,上海市生物医药科技发展中心 |
| |
| 基金项目： | 上海市2021年度科技创新行动计划软科学重点项目“上海重点领域创新链、供应链韧性研究-以生物医药领域为例”(项目编号:21692100400)。 |
| |
| 摘 要： | 为提高我国生物医药科技成果转化率，缩短与美欧等国家和地区差距，推动生物医药产业快速向高能级发展，基于科技创新成果转化理论，从科技成果转化的流程、模式及其相关发展要素等方面对我国生物医药科技成果转化的制约因素进行全面分析，发现创新研发导向偏差、全国性知识网络转化不畅、专项资金支撑不足等是当前影响最为深刻的三大制约因素；据此提出应增强政府政策的针对性和实效性、提升国家创新体系的成果转化效能、全方位打造多层次科技成果转化金融体系等战略规划建议。
|
| 关 键 词： | 生物医药科技成果转化 战略规划 中国 |
| 收稿时间： | 2022/5/31 0:00:00 |
| 修稿时间： | 2023/1/18 0:00:00 |
Analysis of Restrictive Factors and Suggestions of Strategic Planning for the Commercialization of Biopharmaceutical Research and Development in China |
| |
| Abstract: | Based on the relevant theories of the transformation of scientific and technological innovation achievements, this paper comprehensively analyzes the restrictive factors of the commercialization of biopharmaceutical research and development in China from the aspects of the process, model and relevant development factors of the commercialization of biopharmaceutical research and development, and finds that the deviation of the orientation of innovation research and development, the poor commercialization of the national knowledge network, and the lack of special fund support are the three most profound restrictive factors at present. Based on this, it is proposed to strengthen the pertinence and effectiveness of government policies, improve the efficiency of achievements commercialization of the national innovation system, and comprehensively build a multi-level financial system for scientific and technological achievements commercialization. |
| |
| Keywords: | China Commercialization Biopharmaceutical Research and Development |
|
| 点击此处可从《科技管理研究》浏览原始摘要信息 |
| 点击此处可从《科技管理研究》下载免费的PDF全文 |
